Ocular Therapeutix, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $1.9M | $1.8M | $772.0K | $10.0K |
| Cost of Revenue | $457.0K | $443.0K | $319.0K | $91.0K | $7.0K |
| Gross Profit | $1.5M | $1.4M | $1.4M | $681.0K | $3.0K |
| Gross Margin | 76.2% | 76.5% | 81.8% | 88.2% | 30.0% |
| Operating Expenses | |||||
| Research & Development | $30.9M | $27.1M | $26.6M | $18.9M | $11.5M |
| SG&A Expense | $15.5M | $11.0M | $9.2M | $6.9M | $1.5M |
| Operating Income | $-61.9M | $-43.3M | $-38.2M | $-27.1M | $-13.7M |
| Operating Margin | -3,220.1% | -2,296.0% | -2,182.7% | -3,509.6% | -136,710.0% |
| Interest Expense | $1.9M | $1.7M | $1.7M | $1.1M | $377.0K |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-63.4M | $-44.7M | $-39.7M | $-28.6M | $-14.1M |
| Net Margin | -3,296.2% | -2,369.0% | -2,271.3% | -3,710.9% | -140,930.0% |
| EPS (Basic) | $-2.20 | $-1.80 | $-1.71 | $-2.69 | $-5.60 |
| EPS (Diluted) | $-2.20 | $-1.80 | $-1.71 | $-2.69 | $-5.60 |
| Shares Outstanding (Basic) | 29.7M | 25.0M | 24.8M | 21.3M | — |
| Shares Outstanding (Diluted) | 29.7M | 25.0M | 24.8M | 21.3M | — |
| Dividends Per Share | — | — | — | — | — |